Author/Authors :
Bui، نويسنده , , V. and Sheh، نويسنده , , Y. and Finn، نويسنده , , R. and Francesconi، نويسنده , , L. and Cai، نويسنده , , S. and Schlyer، نويسنده , , D. and Wieland، نويسنده , , B.، نويسنده ,
Abstract :
The past decade has witnessed the applications of positron emission tomography (PET) evolving from a purely research endeavor to a procedure which has specific clinical applications in the areas of cardiology, neurology and oncology. The growth of PET has been facilitated by developments in both medical instrumentation and radiopharmaceutical chemistry efforts. Included in this latter effort has been the low energy accelerator production and processing of unique PET radionuclides appropriate for the radiolabeling of biomolecules, i.e. monoclonal antibodies and peptides. The development and application of electroplated targets of antimony and copper for the production of iodine-124 and gallium-66 respectively, utilizing the Memorial Sloan-Kettering Cancer Center (MSKCC) cyclotron are examples of target design and development applicable to many medical accelerators.
